Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club
Production & Manufacturing
Manufacturing
Return to: PBR Home | Production & Manufacturing | Manufacturing

NanoSonic signs Trappsol Cyclo manufacturing agreement with Biologix

PBR Staff Writer Published 23 February 2012

NanoSonic Products, a wholly owned subsidiary of CTD Holdings, has signed a manufacturing agreement with Florida Biologix for the production of the sterile liquid form of its Trappsol Cyclo product.

Trappsol Cyclo product is an orphan drug-designated treatment for Niemann Pick Type-C disease, also known as Childhood Alzheimer's.

The product is currently being administered in the US under a compassionate use IND, the company said.

NanoSonic Products president and CEO Jeffrey Tate said manufacturing of the liquid form of their Trappsol Cyclo is the first step in their stability testing project for this product.

"Obtaining stability data for this form of our product is a top priority, and the opportunity to work with Florida Biologix's manufacturing experts will move it forward quickly," Tate added.

Comments
Post a comment

Comments may be moderated for spam, obscenities or defamation.